SCHEMBL20206729

SCHEMBL20206729

COc1cccc2c1NCCO2

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTNNB1 P35222 1/20 0.40
WNT3A P56704 1/20 0.40
EGFR P00533 2/20 0.39
ADRA2A P08913 3/20 0.38
ADRA1D P25100 3/20 0.38
ADRA1A P35348 3/20 0.38
ADRA1B P35368 3/20 0.38
MAPT P10636 3/20 0.38
ADRA2C P18825 2/20 0.38
ALDH1A1 P00352 2/20 0.38
GAA P10253 2/20 0.38
ADRA2B P18089 1/20 0.38
HSD17B10 Q99714 1/20 0.38
PARP1 P09874 1/20 0.37
HTR5A P47898 1/20 0.36
TP53 P04637 1/20 0.36
CA12 O43570 1/20 0.35
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35
CA4 P22748 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3115776 0.77 ALDH1A1 (0.44) ADRA2AADRA1DADRA1AADRA1BMAPT
SCHEMBL4894342 0.75 GRM5 (0.46) MAPTALDH1A1
SCHEMBL30517094 0.73 ALOX5 (0.51) CTNNB1WNT3AADRA1DADRA1AADRA1B
SCHEMBL984368 0.73 ALOX5 (0.51) CTNNB1WNT3AADRA1DADRA1AADRA1B
SCHEMBL15202099 0.73 FABP6 (0.40) ADRA2AADRA1DADRA1AADRA1BMAPT
SCHEMBL5248739 0.73 ITGB2 (0.38) EGFRADRA2AADRA1DADRA1AADRA1B
SCHEMBL16404623 0.73 MAPT (0.43) EGFRADRA2AADRA1DADRA1AADRA1B
SCHEMBL20756201 0.73 ADRA2A (0.40) ADRA2AADRA1DADRA1AADRA1BMAPT
SCHEMBL30641376 0.73 ADRA2A (0.40) ADRA2AADRA1DADRA1AADRA1BMAPT
SCHEMBL30343091 0.73 ITGB2 (0.38) ADRA2AADRA1DADRA1AADRA1BMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025091026-A1 THERAPEUTIC COMPOSITIONS CONTAINING G-CLAMP PNA AND USES THEREOF UNIVERSITY OF CONNECTICUT (US) 2025-05-01 WO claimed
WO-2025091026-A1 THERAPEUTIC COMPOSITIONS CONTAINING G-CLAMP PNA AND USES THEREOF UNIVERSITY OF CONNECTICUT (US) 2025-05-01 WO disclosed
US-20230150978-A1 QUINAZOLINONE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER ENYO PHARMA (FR) 2023-05-18 US disclosed
EP-4126847-A1 QUINAZOLINONE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER ENYO Pharma (FR) 2023-02-08 EP disclosed
US-11174271-B2 6-membered uracil isosteres CV6 THERAPEUTICS (NI) LIMITED (GB) 2021-11-16 US disclosed
WO-2021198188-A1 QUINAZOLINONE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER ENYO PHARMA (FR) 2021-10-07 WO disclosed
US-20190270756-A1 6-MEMBERED URACIL ISOSTERES CV6 THERAPEUTICS (NI) LIMITED (GB) 2019-09-05 US disclosed
WO-2018098204-A1 6-MEMBERED URACIL ISOSTERES CV6 THERAPEUTICS (NI) LIMITED (GB) 2018-05-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230150978-A1 QUINAZOLINONE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER NQO2, NQO1, NDUFV2 CTNNB1 3127/4885WNT3A 2218/4885EGFR 1930/4885
US-11174271-B2 6-membered uracil isosteres UNG, DUT, DPYD CTNNB1 2830/4885WNT3A 3687/4885EGFR 3945/4885
US-20190270756-A1 6-MEMBERED URACIL ISOSTERES UNG, DUT, DPYD CTNNB1 2830/4885WNT3A 3687/4885EGFR 3945/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.